Biotech Startups

Synonym builds tools for biomanufacturing companies to model bioprocesses, run techno-economic analysis, and find production facilities. Its platform includes engineering solutions for cost and viability modeling and a facility-matching network that connects companies to fermentation and bioproduction capacity.

4 investors

Synova Life Sciences develops technology for biomedical applications, focusing on innovative solutions in the life sciences sector.

4 investors

Synthio Labs develops AI-powered synthesis and clinical interpretation systems for pharmaceutical interactions, offering text, voice, and video interfaces designed for healthcare professionals and patients that integrate FDA labels, drug mechanisms, and clinical literature.

4 investors

T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs. The company combines expertise in biopharmaceutical drug development, single cell genomics, machine learning, and structural biology.

4 investors

T-Cypher Bio develops drugs with curative potential, focusing on antibody development, T cell biology, and TCR discovery. The company applies immunology and AI-driven approaches in the biotech sector.

4 investors

T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors. It engineers fully human, tumor-specific T cell receptors along with novel CD8 coreceptors and switch receptors, using technology developed at the Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin.

4 investors

Taconic Biosciences provides genetically engineered mouse and rat models, humanized immune system mice, custom model generation, colony management, and in vivo research services. It serves drug discovery and preclinical researchers, offering integrated laboratory animal models and services from model selection through study-ready cohorts.

4 investors

Tactogen develops patented new chemical entities, including benzofuran-based compositions, and conducts preclinical research and publishes data on these compounds. The company operates in the neuroscience and pharmaceutical drug development space.

4 investors

Tagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.

4 investors

Tahoe Bio AI applies machine learning and computational biology to drug discovery and development. The company leverages AI and advanced cellular modeling for pre-clinical research in the biotech industry.

4 investors

Talam Biotech develops natural, microbial-based products aimed at challenges in agriculture and food systems. The company focuses on turning scientific discovery into EPA-approved, commercially viable crop input solutions.

4 investors

Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease. This page is a board/leadership team bio page.

4 investors

Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye. The company works with eye care professionals to advance therapies in the ophthalmology market.

4 investors

Ternary develops AI-driven drug discovery technology focused on targeted protein degradation and induced proximity platforms. The company serves pharmaceutical and biotech organizations seeking computational approaches to identify novel therapeutic targets.

4 investors

Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program. As of May 5, 2026, it operates as a subsidiary of Merck & Co., Inc. (known as MSD outside the US and Canada).

4 investors

Terrestrial is developing the Tacterra microarray patch (MAP) platform, which uses dissolvable tips made from biomaterials to deliver therapies such as GLP-1 through the skin without injections. The platform is designed for patient self-administration at home or while traveling, removing the need for sharps and refrigeration.

4 investors

GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients. Its research focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

4 investors

TET Medical develops diagnostics, working in collaboration with Cornell University's research and facilities. The company is supported by administrative and operational staff focused on efficiency and compliance.

4 investors

Biotechnology company with proprietary technology for ion channel antigens in antibody discovery programs.

4 investors

EVERY produces animal-free egg white proteins using precision fermentation for use as functional ingredients in food and beverage applications. The company leverages fermentation technology to replicate the nutritional and functional properties of eggs at scale.

4 investors

SyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists. The company builds an internal oncology pipeline and partners with external organizations to expand adoption of its platform.

4 investors

Sanofi is an R&D-driven, AI-powered biopharmaceutical company that develops medicines and vaccines, with a focus on immunology and the immune system. It maintains a clinical pipeline spanning multiple therapeutic areas for patients worldwide.

4 investors

Takeda is a global pharmaceutical company that develops medicines and treatments for patients, focused on advancing science, technology, and partnerships to create new standards of care.

4 investors

TISSIUM develops biomorphic polymer technology, including proprietary polymers, activation technologies, and delivery devices, to reconstruct damaged tissue and restore its function across multiple therapeutic areas. The company operates an integrated innovation, design, manufacturing, and commercialization platform serving its own programs and co-development partnerships in the medtech industry.

4 investors